First-ever phase-three clinical trial for dengue vaccine initiated in India
The Indian Council of Medical Research (ICMR) and Panacea Biotec Limited on Wednesday announced the initiation of the first ever phase 3 clinical trial for a dengue vaccine in India.
The trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll has been developed by Panacea Biotec. The first participant in this trial was vaccinated on Wednesday at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak.
The tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health, U.S., has shown promising results in preclinical and clinical trials worldwide. (Foreign Agencies)
The post First-ever phase-three clinical trial for dengue vaccine initiated in India appeared first on DailyNews.